Proteon Therapeutics, Inc. (PRTO) Stock: Is This Biotechnology Stock Worth Your Consideration?


Proteon Therapeutics, Inc. (PRTO) is making a move down in the market in today’s trading session. The company, one that is focused in the biotech sector, is currently trading at $3.42 after tumbling -6.30% so far today. In terms of biotechnology stocks, there are quite a few aspects that have the ability to cause movement in the market. One of the most common is news. Here are the recent stories associated with PRTO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-13-19 08:17AM Proteon Therapeutics: 4Q Earnings Snapshot
08:00AM Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Mar-04-19 04:30PM Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
Feb-12-19 09:25AM 4 Healthcare Stocks Looking To Set February Highs
Jan-24-19 08:00AM Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease

Nonetheless, when making an investing decision, prospective investors should look into far more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happening with Proteon Therapeutics, Inc..

Trends That We’ve Seen From PRTO

Although a move toward the top in a single session, like what we’re seeing from Proteon Therapeutics, Inc. may lead to fear in some investors, that alone should not be the reason for a decision to, or not to, invest in a company. It’s generally a good idea to dig into trends experienced by the stock just a single trading day. As it relates to PRTO, here are the trends that we’ve seen:

  • Past 5 Sessions – In the past week, PRTO has seen a change in value amounting to 1.39%.
  • Past Month – The return from Proteon Therapeutics, Inc. throughout the past month comes to 22.90%.
  • Past Three Months – Over the past 3 months, the company has generated a return of 96.24%
  • Past 6 Months – Throughout the past 6 months, we have seen a change that works out to 69.77% from the stock.
  • This Year So Far – Since the close of last year PRTO has generated a return of 60.79%.
  • Full Year – Finally, in the last year, investors have seen a change that comes to 69.77% out of PRTO. Throughout this period of time, the stock has sold at a high price of -13.20% and a low price of 128.00%.

Rations That Investors Should Consider

Digging into various ratios having to do with a stock can give investors a view of how dangerous and/or potentially profitable a an investment option might be. Here are a few of the most important ratios to look at when digging into PRTO.

Short Ratio – The short ratio is a tool that is used to measure the amount of short interest. As the ratio heads up, it means that more investors are expecting that the stock is going to tumble. In general, biotechnology stocks can carry a higher short ratio. However, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Proteon Therapeutics, Inc., the stock’s short ratio amounts to 5.22.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay its debts when they come due with only current assets or quick assets. In the biotechnology industry, several companies rely heavily on the continuation of investor support, the current and quick ratios can look upsetting. Nonetheless, several better companies in the biotech space come with great quick and current ratios. In terms of PRTO, the quick and current ratios add up to 7.50 and 7.50 respectively.  

Book To Share Value – The book to share value compares the value of assets owned by the company to the share price of the stock. when it comes to Proteon Therapeutics, Inc., the book to share value ratio comes in at -0.06.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of the company’s stock. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to look into. In this case, the cash to share value works out to 1.10.

Analyst Opinions Of Proteon Therapeutics, Inc.

Although it’s rarely a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their thoughts when validating your own thoughts before making an investment decision in the biotech industry. Below are the most recent moves that we have seen from analysts with regard to PRTO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-11-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform $9
Oct-30-18 Initiated Maxim Group Buy $5
Mar-17-17 Downgrade H.C. Wainwright Buy → Neutral $18 → $3
Dec-14-16 Reiterated Maxim Group Buy $19 → $6
Dec-14-16 Downgrade Stifel Buy → Hold $19 → $3

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PRTO, here’s what we’re seeing:

  • Institutions – At the moment, institutions hold 69.30% of PRTO. Nonetheless, it is important to note that the ownership held by institutions has changed in the amount of -1.40% throughout the last 3 months.
  • Insider Holdings – with regard to insiders, members of the management team and others close to PRTO currently hold 1.10% of the company. Insider ownership of the company has moved 0.00% throughout the last 3 months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 19.97M shares of Proteon Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PRTO has a float of 17.34M.

I also find it important to pay attention to the short percent. After all, when a high portion of the float is sold short, the overall opinion in the market is that the stock is headed for a deep dive. As far as PRTO, the percentage of the float that is shorted is 4.91%. Most traders believe that a concerning short percent of the float would be considered to be anything over 40%. Nonetheless, I’ve seen that a short percent of the float over 26% is generally a risky play.

What We’ve Seen In Financial Results

What have ween seen from PRTO in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – Currently, analysts expect that Proteon Therapeutics, Inc. will create earnings per diluted share coming to a total of -0.84, with -0.26 being announced in the earnings report for the current quarter. Although this is not earnings driven, because we are chatting on the topic of Wall Street analysts, PRTO is presently rated a 2.40 on a scale from 1 to 5 on which 1 is the worst possible analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the last half decade, Proteon Therapeutics, Inc. has generated a movement in revenue that works out to 0. EPS through the last half decade have seen a change of -2.80%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly explained in today’s society, the company has experienced a change in earnings that comes to a total of 13.20%. The company has also seen a change when it comes to sales in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I’m highly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! While, my builder made it possible for me to learn, it is far simpler to do so through the receipt of feedback from humans. Below this article, you will find a section for comments. If you would like for me consider other data, tweak the way provide data, comprehend data from a different perspective, or just about anything else, I’d love to know. If you’ve got something to offer consider leaving a comment below. I’ll process that comment and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here